CRACR · Crown Reserve Acquisition Corp. I Rights

Crown Reserve Acquisition Corp. I, a SPAC listed on Nasdaq (CRAC, CRACU, CRACW, CRACR), has entered a definitive Business Combination Agreement with Carvix, Inc., a Delaware-based technology-driven automotive platform. The structure involves a merger of a Crown Reserve subsidiary into Carvix, with Carvix surviving as a wholly owned subsidiary, followed by Crown Reserve's domestication from Cayman Islands to Delaware. The combined entity anticipates Nasdaq listing. Key to investor interest is the $1.0 billion implied enterprise value for Carvix, structured as an all-stock deal using a $10 per share reference, which sets the pro forma capitalization baseline. Financing commitments include reasonable best efforts for $80 million PIPE and $20 million equity line, with a firm $10 million minimum cash condition post-redemptions and expenses, addressing common SPAC redemption risks. The earnout mechanism incentivizes performance, offering up to 50 million shares to Carvix stockholders (split evenly between revenue and EBITDA milestones) and 3 million to the Sponsor over four years starting 2027, with catch-up provisions. Governance balances control with four Carvix board seats (including one independent) and one Sponsor independent, while Carvix's management continuity supports operational expertise in acquiring and scaling automotive businesses. Lock-ups (18 months for insiders, Sponsor variant) align interests. The deal's tax-free intent and standard conditions (shareholder votes, S-4, Nasdaq approval, no MAE) follow SPAC norms, with a September 30, 2026 outside date. Key stockholder support agreements reduce approval risks, positioning this as a transformative merger for Crown Reserve into the automotive services sector.